Abstract: Background: Daptomycin dose is adjusted to body weight and renal function and is usually not guided by therapeutic drug monitoring (TDM). Daptomycin plasma concentration measurement was established at our institution in January 2009 and is now increasingly being used. The aim of this study was to describe and characterize variability in daptomycin exposure during routine clinical therapy. Methods: We collected daptomycin plasma concentrations that were measured at our institution during the period January 2009-July 2012. Additional clinical and demographic data and their association with daptomycin exposure was tested by a multilevel linear regression analysis. Results: A total of 332 daptomycin plasma concentrations were determined in 86 patients. 66% (n=218) of all determinations were trough concentrations (Cmin) and 34% (n=114) were peak concentrations (Cmax). Cmin ranged 2-68mg/L (median 16.7mg/L) and Cmax 20-236mg/L (median 66.2mg/L). A significant positive association of total dose, albumin, creatinine, and a significant negative association of dose interval and intermittent haemodialysis with Cmin was found in the regression analysis. Total dose and Intensive Care Unit (ICU) − staywassignif icantlyassociatedwithCmax(P < 0.05).However, only28%(P < 0.005)of Cminvariabilityand8%(P = 0. 
35
Results: A total of 332 daptomycin plasma concentrations were determined in 86 patients. 66%
36
(n=218) of all determinations were trough concentrations (Cmin) and 34% (n=114) were peak 
67
/MIC ratio being the main determinants of bactericidal effect [4, 5] .
68
Based on these findings, higher doses are recommended in severe and difficult to treat positive infections, such as bacteraemia, infective endocarditis and osteomyelitis [6] , and in 70 critically ill patients [7] . Daptomycin use and efficacy in different types of infection has mainly 71 been investigated in retrospective studies [8, 9] where the focus was to investigate dosing 72 regimen and outcome; daptomycin plasma concentrations were not determined in these studies.
73
As daptomycin is mainly eliminated by the kidneys, prolongation of dosing interval from 24 74 hours (q24h) to 48 hours (q48h) is indicated in patients with a reduced glomerular filtration rate 75 4 (GFR) of <30mL/min with or without intermittent haemodialysis. Independent of the degree of 76 renal impairment und type of renal replacement therapy used, high variability of daptomycin 77 plasma concentrations can occur [10] [11] [12] . This is particularly the case in critically ill patients 78 with Gram-positive sepsis, higher volume of distribution and increased daptomycin clearance 79 has been observed with highly variable drug exposure leading to very low drug concentration in 80 certain patients [7, 13, 14] . Therefore, TDM in these special populations might be warranted to 
Material and Methods

90
In this retrospective chart review, we included all patients treated with daptomycin at the 
116
The independent association between daptomycin trough levels (Cmin), peak levels (Cmax) 13.8mg/kg) was administered.
155
In 10 patients, dose was adjusted based on daptomycin plasma concentration measurements.
156
However, this was done in an unsystematic way solely dependent on the decision of the treating 157 physician as no internal guidelines on target range were available. In 4 patients, the dose was 
175
The highest variability of daptomycin plasma concentrations was observed in patients with
176
CrCl ≤30mL/min and CrCl >30mL/min without renal replacement therapy (CV% 81% and 
184
This difference was statistically significant (student T-test p<0.05).
185
Cmin levels were significantly lower in patients with CRRT compared to patients without renal Cmin variability and more than 90% of the Cmax variability remains unexplained in our model.
233
Renal function has been identified as the main factor associated with daptomycin clearance in acute bacterial infections [7, 13, 14] and in patients with severely impaired renal function [18] .
238
In a subset of patients with MRSA bacteraemia, highly increased daptomycin clearance was 239 observed with significantly lower daptomycin exposure despite a comparable dose 240 administered in all patients [7] . However, a significant proportion of daptomycin clearance 241 variability remained unexplained [14, 18] . In view of these findings, TDM may me considered 242 an important tool for individualized daptomycin dosing [7] .
243
Over one third of the subjects in our study were treated with a high dose regimen >6mg/kg. with regard to dose, duration of therapy and surgical interventions.
296
As we included only patients with daptomycin TDM performed, the population studied 297 probably represents only a subset of the overall population treated with daptomycin at our 298 institution. 50% of Cubicin® was in fact delivered to departments other than ICUs during the 299 period of data collection, whereas 80% of our study patients were hospitalized in the ICU.
301
Conclusion
302
Our data demonstrate that, in an unselected patient population, daptomycin exposure is highly 303 variable and is only partially explained by dose administered and underlying renal function.
304
The factors accounting for most of the variability remains unclear and therefore daptomycin 
